115 related articles for article (PubMed ID: 21764590)
1. N-substituted homopiperazine barbiturates as gelatinase inhibitors.
Wang J; Medina C; Radomski MW; Gilmer JF
Bioorg Med Chem; 2011 Aug; 19(16):4985-99. PubMed ID: 21764590
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.
Nicolotti O; Catto M; Giangreco I; Barletta M; Leonetti F; Stefanachi A; Pisani L; Cellamare S; Tortorella P; Loiodice F; Carotti A
Eur J Med Chem; 2012 Dec; 58():368-76. PubMed ID: 23149299
[TBL] [Abstract][Full Text] [Related]
3. Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.
Wang J; O'Sullivan S; Harmon S; Keaveny R; Radomski MW; Medina C; Gilmer JF
J Med Chem; 2012 Mar; 55(5):2154-62. PubMed ID: 22248361
[TBL] [Abstract][Full Text] [Related]
4. MMP inhibition by barbiturate homodimers.
Wang J; Radomski MW; Medina C; Gilmer JF
Bioorg Med Chem Lett; 2013 Jan; 23(2):444-7. PubMed ID: 23246356
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting with a selective gelatinase inhibitor.
Koivunen E; Arap W; Valtanen H; Rainisalo A; Medina OP; Heikkilä P; Kantor C; Gahmberg CG; Salo T; Konttinen YT; Sorsa T; Ruoslahti E; Pasqualini R
Nat Biotechnol; 1999 Aug; 17(8):768-74. PubMed ID: 10429241
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix metalloproteinases.
Faust A; Waschkau B; Waldeck J; Höltke C; Breyholz HJ; Wagner S; Kopka K; Heindel W; Schäfers M; Bremer C
Bioconjug Chem; 2008 May; 19(5):1001-8. PubMed ID: 18396900
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of a highly selective gelatinase inhibitor generates active metabolite.
Lee M; Villegas-Estrada A; Celenza G; Boggess B; Toth M; Kreitinger G; Forbes C; Fridman R; Mobashery S; Chang M
Chem Biol Drug Des; 2007 Nov; 70(5):371-82. PubMed ID: 17927722
[TBL] [Abstract][Full Text] [Related]
8. C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.
Breyholz HJ; Schäfers M; Wagner S; Höltke C; Faust A; Rabeneck H; Levkau B; Schober O; Kopka K
J Med Chem; 2005 May; 48(9):3400-9. PubMed ID: 15857146
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes.
Mäkelä M; Larjava H; Pirilä E; Maisi P; Salo T; Sorsa T; Uitto VJ
Exp Cell Res; 1999 Aug; 251(1):67-78. PubMed ID: 10438572
[TBL] [Abstract][Full Text] [Related]
10. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
[TBL] [Abstract][Full Text] [Related]
11. A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent.
Lim IT; Brown S; Mobashery S
J Org Chem; 2004 May; 69(10):3572-3. PubMed ID: 15132575
[TBL] [Abstract][Full Text] [Related]
12. Regulation of matrix metalloproteinase-2 production by cytokines and pharmacological agents in human pulp cell cultures.
Chang YC; Yang SF; Hsieh YS
J Endod; 2001 Nov; 27(11):679-82. PubMed ID: 11716080
[TBL] [Abstract][Full Text] [Related]
13. In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.
Topai A; Breccia P; Minissi F; Padova A; Marini S; Cerbara I
Bioorg Med Chem; 2012 Apr; 20(7):2323-37. PubMed ID: 22386984
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).
Kim SH; Pudzianowski AT; Leavitt KJ; Barbosa J; McDonnell PA; Metzler WJ; Rankin BM; Liu R; Vaccaro W; Pitts W
Bioorg Med Chem Lett; 2005 Feb; 15(4):1101-6. PubMed ID: 15686921
[TBL] [Abstract][Full Text] [Related]
15. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2.
Deryugina EI; Bourdon MA; Reisfeld RA; Strongin A
Cancer Res; 1998 Aug; 58(16):3743-50. PubMed ID: 9721888
[TBL] [Abstract][Full Text] [Related]
16. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
Lim YT; Sugiura Y; Laug WE; Sun B; Garcia A; DeClerck YA
J Cell Physiol; 1996 May; 167(2):333-40. PubMed ID: 8613475
[TBL] [Abstract][Full Text] [Related]
17. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor.
Krüger A; Arlt MJ; Gerg M; Kopitz C; Bernardo MM; Chang M; Mobashery S; Fridman R
Cancer Res; 2005 May; 65(9):3523-6. PubMed ID: 15867341
[TBL] [Abstract][Full Text] [Related]
18. Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.
Chen MH; Cui SX; Cheng YN; Sun LR; Li QB; Xu WF; Ward SG; Tang W; Qu XJ
Anticancer Drugs; 2008 Nov; 19(10):957-65. PubMed ID: 18827560
[TBL] [Abstract][Full Text] [Related]
19. Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.
Szardenings AK; Harris D; Lam S; Shi L; Tien D; Wang Y; Patel DV; Navre M; Campbell DA
J Med Chem; 1998 Jun; 41(13):2194-200. PubMed ID: 9632351
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases.
Bernardo MM; Brown S; Li ZH; Fridman R; Mobashery S
J Biol Chem; 2002 Mar; 277(13):11201-7. PubMed ID: 11790786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
